Chronos Archive seal

Review checklist: Franklin D. Roosevelt (HR-ET002)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review.
provenance reviewnot_startedNPS, FDR Library, and PubMed abstract logged; Bruenn's 1970 article not reviewed in full.
safe messaging reviewnot_startedNo behavioral-health content; death recorded without graphic detail.

Judgment calls (dossier editorial resolutions)

  1. Index age. The modern episode presents Roosevelt at 62, his age at the March 27, 1944 examination. The index visit falls on March 27, so the true-date variant lands on the documented examination date. Past medical history and family history include only events before then; the 1945 readings and his death remain in the historical timeline.
  2. Modern diagnosis. Bruenn’s 1944 diagnoses of hypertension, hypertensive heart disease, and left ventricular failure are documented (D). The synthetic episode makes them a modern diagnosis of hypertensive heart failure with reduced ejection fraction, treated with therapies that did not exist in 1944.
  3. Contested cause of paralysis. The contemporaneous diagnosis was polio, so the problem list records sequelae of poliomyelitis (ICD-10-CM B91), verification provisional. The Guillain-Barré proposal is graded R and kept off the active problem list.
  4. Anemia. The 1941 anemia is documented in a secondary source and graded D with certainty probable. The modern iron deficiency is synthetic and is linked to it, not derived from it.
  5. Disability. He uses a wheelchair throughout the episode. Height is reported, weight is measured on a wheelchair scale, and heart failure symptoms are judged by wheelchair propulsion and orthopnea rather than walking distance.
  6. Sick and preventive visits. Two visits were added to the chronic-care schedule: an unscheduled sick visit on July 27, 2026 (true frame July 27, 1944) for a viral gastroenteritis, and a periodic adult preventive visit on October 23, 2026 (true frame October 23, 1944). Both are synthetic. He is 62, so the visit follows USPSTF adult preventive services rather than a Medicare wellness visit. The gastroenteritis does not echo a documented illness. It was chosen because volume depletion tests the sick-day handling of sacubitril/valsartan, spironolactone, and empagliflozin, with carvedilol continued, and because diarrhea raises transfer-fall and skin risks for a wheelchair user; the creatinine rise is kept below the threshold for acute kidney injury and recovers by the September review. The preventive visit uses the documented heavy smoking to make him eligible for lung cancer screening. It replaces gait and falls screening with transfer safety, pressure-injury, and shoulder checks. It records no skin-lesion finding, because the melanoma hypothesis is not used, and no new weakness or post-polio diagnosis, so the contested cause of paralysis is not extended. Hepatitis C and HIV screening, the low-dose CT, and the stool test are ordered, and their results are not recorded. Its advance care planning names no real person as his health care agent.
  7. Focused visits. The three chronic-care follow-ups (two weeks, three months, and six months) are documented as focused visits on the CMID heart failure, hypertension, hyperlipidemia, and anemia monographs; the diabetes monograph has no prediabetes surveillance section, so yearly HbA1c follows the hypertension monograph and the USPSTF. Each visit lists every item the protocols call for at that point, with its interval and status. Synthetic findings introduced: the two-week examination (jugular venous pressure 9 cm, basal crackles, S3, 1+ edema) and later examinations, home weight and blood pressure logs, palpable foot pulses at six months, a cardiac rehabilitation referral in June adapted for a wheelchair user with arm ergometry and resistance bands (consistent with the band exercise recorded at the preventive visit), and his preference at six months to keep sacubitril/valsartan 49/51 mg and carvedilol 12.5 mg below target doses to protect transfer safety, which is how the goal of highest tolerated doses is read. Protocol deviations recorded instead of invented results: no ECG and no liver panel from the diagnostic workup; no basic metabolic panel one to two weeks after the April sacubitril/valsartan increase and spironolactone start; no panel one to two weeks after furosemide stopped in June; no panel within two weeks of restarting the medicines held during the July illness (the sick visit deferred it to September); magnesium never measured with any panel; the post-statin lipid panel drawn at 26 weeks instead of 4 to 12; and iron studies drawn ten weeks after intravenous iron instead of six to eight, a delay planned in April to spare a trip. Later results show no harm from any of them. Endoscopy for iron deficiency is recorded as not indicated, because ferritin 48 ng/mL is above the 30 ng/mL threshold for absolute iron deficiency.
  8. Consultation. The cardiology referral and Dr. Castellanos's consultation on the day of the two-week visit are synthetic and are written to agree with the record: the titration, spironolactone, intravenous iron, and pneumococcal vaccination that day, the later furosemide stop, cardiac rehabilitation, and the repeat echocardiogram. Synthetic details introduced: the echocardiogram description (dilated, globally hypokinetic left ventricle without regional wall motion abnormality or significant valve disease) alongside the recorded ejection fraction of 30 percent. Judgment calls: (1) an ischemic evaluation is deferred unless the ejection fraction fails to improve or angina develops; the ejection fraction later rose to 45 percent, so none is recorded; (2) the consultant notes that no ECG is on file and asks for one before any device decision, matching the deviation recorded at the visit; no device decision became necessary.
  9. Not used. The melanoma hypothesis about his final illness was not verified for this case and is not recorded. The completeness of Bruenn’s 1970 account is debated by historians; the case relies on the two sources that summarize it.
  10. Roosevelt died in 1945, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-04-10
Progress note 02 (C-CDA)
12-lead ECGAt initial evaluation; repeat with symptom change, arrhythmia, or device considerationNo ECG from the diagnostic workup is on file, a deviation from the protocol. Rhythm is regular on examination and no device decision is due yet, so no harm has resulted. Corrective action: obtain an ECG before the device decision that follows the repeat echocardiogram
2026-04-10
Progress note 02 (C-CDA)
Liver tests (initial workup; ALT before starting a statin)Once at diagnosisNo liver panel from the diagnostic visit is on file, a deviation from the heart failure and lipid protocols. He has no symptoms of liver injury. Routine liver monitoring on a statin is not recommended, so the corrective action is to test ALT only if symptoms appear
2026-06-26
Progress note 03 (C-CDA)
Basic metabolic panel 1 to 2 weeks after the April changesOnce, after titrating sacubitril/valsartan and starting spironolactoneNot drawn in the window: the panel planned for the second iron infusion was not done, a deviation from the protocol. Today's potassium and kidney function are normal, so no harm resulted. Corrective action: each medication change now comes with a dated laboratory appointment booked before he leaves
2026-06-26
Progress note 03 (C-CDA)
Lipid panel4 to 12 weeks after starting a statinNot drawn in the window, which closed last week, and not on today's order, a deviation from the lipid protocol. He takes every dose and has no muscle symptoms, and a three-month delay in confirming the response carries little risk. Corrective action: added to the six-month laboratory order
2026-09-25
Progress note 05 (C-CDA)
Basic metabolic panel after stopping furosemide in June1 to 2 weeks after a diuretic changeNot drawn in the window, a deviation from the protocol. The next panel was at the July sick visit, about four and a half weeks later, with potassium 4.9 during volume depletion; today's potassium is 4.5, so no harm resulted. This is the second missed post-change check this year; the corrective action is the dated laboratory appointment at every medication change
2026-09-25
Progress note 05 (C-CDA)
Basic metabolic panel after restarting the medicines held in July1 to 2 weeks after restarting sacubitril/valsartan, spironolactone, and empagliflozinThe sick-visit plan moved the recheck to today; strictly, the protocol calls for a panel within two weeks of a restart, so this is recorded as a deviation. Today's potassium and creatinine are at baseline, so no harm resulted. Corrective action: a panel one to two weeks after any future sick-day restart
2026-09-25
Progress note 05 (C-CDA)
MagnesiumWith each basic metabolic panelNot measured with any panel since diagnosis, a deviation from the protocol. He has had no arrhythmia or cramps and has been off the loop diuretic since June, so the risk of low magnesium is small. Corrective action: added to the three-month panel
2026-09-25
Progress note 05 (C-CDA)
12-lead ECGAt initial evaluation; repeat with device considerationStill not on file, a deviation carried from April. No device decision is needed now that the ejection fraction is 45 percent, and his rhythm is regular, so no harm has resulted. Corrective action: ECG at the three-month review

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-06-26
Progress note 03 (C-CDA)
ReferralCardiac rehabilitationReferredEligible: ejection fraction 30 percent, NYHA II, three months of therapy, no hospital stay. Referred to a program that adapts training for wheelchair users with arm ergometry and resistance bands
2026-10-23
Progress note 06 (C-CDA)
PreventionLung cancer screeningOrderedMore than 30 pack-years and quit six months ago. After shared decision-making about benefits, false positives, and radiation, he chose annual low-dose CT; first scan ordered
2026-10-23
Progress note 06 (C-CDA)
PreventionColorectal cancer screeningOrderedNo prior screening on record. Options discussed; because bowel preparation and the toileting it requires are hard for him, he chose a yearly fecal immunochemical test, and a kit was given today. A positive test needs colonoscopy
2026-10-23
Progress note 06 (C-CDA)
PreventionHepatitis C and HIV screeningOrderedOne-time screening recommended for all adults in these age ranges; no prior result on record; added to the next blood draw

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0004A 2003 Bayesian analysis of the recorded symptoms concluded that Guillain-Barré syndrome was more probable than paralytic polio as the cause of Roosevelt's 1921 illness; the conclusion is disputed and cannot be confirmed because no cerebrospinal fluid was examined.disputed

Sensitive claims

None.

Diagnoses not confirmed

ProblemCodeVerificationReason
Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputedB91provisionalSynthetic modern coding of the documented diagnosis; the alternative cause remains R.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-03-27NT-proBNP2850 pg/mL (high)High
2026-03-27Glucose104 mg/dL (high)High
2026-03-27Hemoglobin12.6 g/dL (low)Low
2026-03-27Transferrin saturation16% (low)Low
2026-03-27LDL cholesterol132 mg/dL (high)High
2026-03-27HbA1c5.9% (high)High
2026-03-27Urine albumin-creatinine ratio64 mg/g (high)High
2026-04-10LVEF by echocardiogram30% (low)Low
2026-06-26NT-proBNP980 pg/mL (high)High
2026-09-25NT-proBNP410 pg/mL (high)High
2026-09-25LVEF by echocardiogram45% (low)Low
2026-07-27Creatinine1.42 mg/dL (high)High
2026-07-27eGFR56 mL/min/1.73 m² (low)Low